Mazdutide (IBI362)

Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes

Weight: 4,563.1 Da
Half-life: 6-8 days
Chain: 33 amino acids
4 studies
2025 latest
Extensively Studied
Dose Start 1.5-3mg weekly, titrate up to 6-9mg based on response
Frequency Once weekly injection
Cycle 48-60+ weeks for optimal results per clinical trials
Storage Refrigerate reconstituted solution at 2-8°C, use within 30 days; lyophilized powder at -20°C until reconstitution
Accumulation Plotter

Community Research

Join others researching Mazdutide — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.

Mechanism of Action

Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects.

01 Up to 20% body weight loss
02 Superior glycemic control versus semaglutide
03 Increased energy expenditure via glucagon receptor activation
04 Improved cardiometabolic markers (BP, lipids, liver fat)
05 Once-weekly injection convenience

Molecular Data

Molecular Weight
4,563.1 Da
Chain Length
33 amino acids
Type
Oxyntomodulin analog with fatty acid conjugation
Amino Acid Sequence
33-amino acid linear synthetic peptide

Complex or non-standard sequence format

Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Weight Loss
Severe Obesity Management most effective

GLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction.

Metabolic Syndrome Improvement most effective

Significant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%).

Liver Fat Reduction most effective

Exploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits.

Type 2 Diabetes
Glycemic Control most effective

HbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%.

Dual Endpoint Achievement most effective

48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide.

Cardiovascular
Blood Pressure Reduction effective

Systolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials.

Lipid Profile Enhancement effective

Total cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.

Dosing Protocols

Subcutaneous injection delivering dual GLP-1/glucagon agonism with once-weekly dosing enabled by fatty acid conjugation.

GoalDoseFrequencyRoute
Weight loss initiation (3mg target)1.5mg → 3mgOnce weeklySubQ
Weight loss progression (4.5mg target)1.5mg → 3mg → 4.5mgOnce weeklySubQ
Weight loss optimization (6mg target)2mg → 4mg → 6mgOnce weeklySubQ
Maximum weight loss (9mg target)3mg → 6mg → 9mgOnce weeklySubQ
T2D management (mild-moderate)3-4.5mg weeklyOnce weeklySubQ

Reconstitution Instructions

Materials Needed:
  • Mazdutide lyophilized powder vial
  • Bacteriostatic water (BAC) for injection
  • Insulin syringes (29-31 gauge)
  • Alcohol prep pads
  • Refrigerator (2-8°C)
  1. 1 Allow vial to reach room temperature (15-20 minutes)
  2. 2 Clean vial top with alcohol swab, air dry completely
  3. 3 Calculate reconstitution volume for desired concentration
  4. 4 Draw bacteriostatic water into syringe, remove air bubbles
  5. 5 Inject BAC water slowly down vial side—drop by drop to prevent foaming
  6. 6 Gently swirl vial in circular motion
  7. 7 Verify complete clarity and colorless appearance
  8. 8 Label vial with reconstitution date and concentration
  9. 9 Store at 2-8°C, use within 30 days

Interactions

!
Semaglutide
Both are GLP-1 agonists; combining increases hypoglycemia and severe GI side effect risk.
avoid
!
Tirzepatide
Both target GLP-1 receptor; additive effects on GI symptoms and hypoglycemia risk.
avoid
!
Liraglutide
Another GLP-1 agonist; dual therapy contraindicated due to additive receptor activation.
avoid
~
Insulin
May require significant dose reduction due to improved glucose control; monitor for hypoglycemia.
monitor
~
Sulfonylureas
Increased hypoglycemia risk; dose reduction may be necessary.
monitor
++
Metformin
Complementary mechanisms; clinical trials allowed stable metformin use with enhanced efficacy.
synergistic
+
BPC-157
No known interactions; may support gut health and potentially reduce GI side effects.
compatible
~
Oral Contraceptives
Delayed gastric emptying may affect absorption; separate administration by 1 hour.
monitor

What to Expect

Week 1-2
Appetite reduction, possible mild nausea, decreased portion sizes
Week 3-4
Early weight loss begins (1-2%), improved satiety after meals
Week 4-8
Dose escalation phase, GI symptoms typically improving, 3-5% weight loss
Week 8-16
Steady weight loss continues (7-12%), energy expenditure effects evident
Week 16-32
Significant weight reduction (12-17%), metabolic markers improving
Week 32-60
Peak effects (up to 20% weight loss), sustained improvements in BP, lipids, glucose

Side Effects & Safety

Common Side Effects

  • Nausea (mild-moderate, typically improves over time)
  • Diarrhea
  • Vomiting
  • Increased heart rate (5-17 bpm observed)

Stop Signs - Discontinue if:

  • Severe or persistent abdominal pain (potential pancreatitis)
  • Neck lumps, hoarseness, or difficulty swallowing
  • Severe nausea/vomiting preventing adequate nutrition or hydration
  • Signs of severe hypoglycemia (confusion, sweating, shakiness)
  • Severe allergic reactions (rash, difficulty breathing, facial swelling)
  • Unusual mood changes, depression, or suicidal thoughts
  • Signs of gallbladder problems (severe upper right abdominal pain)

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • MEN2 syndrome history (class warning for GLP-1 agonists)
  • Pregnancy or breastfeeding (insufficient safety data)

Quality Checklist

Good Signs

  • White to off-white lyophilized powder without clumping or discoloration
  • Completely clear and colorless appearance after reconstitution—no visible particles
  • Intact vial seal and clear labeling with mg dosage, batch numbers, expiration dates

Warning Signs

  • Source verification critical—available from research chemical suppliers

Bad Signs

  • Clumping, discoloration, or moisture in powder
  • Persistent cloudiness or particles after reconstitution indicates degradation

References

  • GLORY-1 Phase 3 Trial
    (2025)

    610 Chinese adults with obesity/overweight; 48 weeks. First Phase 3 weight management trial showing clinically meaningful weight reductions. NEJM.

  • GLORY-2 Phase 3 Trial
    (2025)

    462 Chinese adults with obesity; 60 weeks; 9mg dose. 20.1% weight loss vs 2.8% placebo; 48.7% achieved ≥20% reduction; no plateau observed.

  • DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide
    (2025)

    349 Chinese adults with T2D and obesity; 32 weeks. Mazdutide superiority: 48% vs 21% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001).

  • Phase 2 T2D Trial
    (2024)

    Chinese adults with T2D; 20 weeks. HbA1c reductions 1.41-1.67% vs 0.03% placebo; weight loss up to 7.1%. Diabetes Care.

Related Peptides

BPC-157 compatible

No known interactions; may support gut health and potentially reduce GI side effects.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.